Epifix denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for epifix are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied EpiFix: Duplicate Therapy

EpiFix is a dehydrated human amnion/chorion membrane (dHACM) allograft used in wound care, particularly for chronic wounds such as diabetic foot ulcers and venous leg ulcers. A "duplicate therapy" denial from BCBS typically means the plan determined that another wound care product or service you are already receiving provides the same clinical benefit. This is a contestable determination — EpiFix has a distinct mechanism of action as a regenerative tissue graft and is not clinically interchangeable with standard wound dressings, debridement alone, or other wound care modalities.

## Why This Denial Is Appealable

Duplicate-therapy denials require the insurer to identify the specific existing therapy they believe duplicates EpiFix. Once identified, your appeal can demonstrate that the two treatments are not clinically equivalent — EpiFix is a biologic tissue matrix that delivers growth factors and structural scaffolding, which is mechanistically distinct from conventional wound dressings or topical therapies. Your prescriber is in the best position to articulate this distinction.

## Your Federal Appeal Rights

• Internal appeal: Under ACA Section 2719 and ERISA Section 503, you are entitled to a full-and-fair internal review. Submit within the deadline in your denial letter.
• External review: If the internal appeal is denied, escalate to an Independent Review Organization (IRO) within approximately four months of exhausting internal remedies.
• Expedited review: If your wound is infected, rapidly worsening, or poses a risk of limb loss, request expedited processing at every level.

## Documentation to Gather

• Wound care history: Comprehensive records of all prior and current wound treatments with dates, durations, and outcomes — this is the foundation of a duplicate-therapy rebuttal.
• Current treatment plan: Documentation of all current wound care modalities to clarify what is already being used and why EpiFix is additive, not duplicative.
• Prescriber medical-necessity letter: A letter from your wound care specialist or treating physician explaining the mechanistic distinction between EpiFix and any therapy BCBS identified as duplicative.
• Wound progression records: Wound measurement records, photographs (where available), and nursing or physician notes documenting wound status over time.
• Specialist evaluation: If available, a note from a wound care specialist, vascular surgeon, or podiatrist supporting the treatment plan.

## Criteria-Mapping Structure

Request BCBS's medical policy for EpiFix and the definition of "duplicate therapy" used in your denial. For each element of their determination, provide a documented rebuttal:

| Duplicate-Therapy Claim | Your Rebuttal Evidence | |---|---| | Existing therapy identified as duplicative | Records showing that therapy is distinct and already incorporated in the plan | | Clinical equivalence asserted | Prescriber letter explaining mechanistic distinction of EpiFix | | Medical necessity of adding EpiFix | Wound care history demonstrating inadequate response to existing treatments |

Cross-reference the FDA clearance documentation for EpiFix and BCBS's coverage policy to ensure your appeal addresses every stated criterion.